Connect with us

Health

Telemedicine center becomes effective at Phalebas

RSS

Published

on

PARBAT— A telemedicine center, brought into operation at Thanamaula of Phalebas Municipality-8 in Parbat by the local Char Bhanjyang Service Center has been providing its services to a good number of people.

Locals have been benefited by the operation of center which provides telemedicine services and health counseling for epilepsy, mental problems and other health issues related to urinary system, skin and neurology.

As stated by Char Bhanjyang Health Center’s chief Roshan Gurung, health services have been accessible to the locals with the operation of the telemedicine center.

Telemedicine is about remote delivery of health services by the means of telecommunication and technology through which healthcare providers and patients make a two-way communication, wherein the former listen to the patients problems, evaluate and make diagnosis, and recommend them required treatment or further steps.

ALSO READ :  Ovary removals linked to increased risk of kidney failure

The center provides the services to patients through Skype where medical specialists and doctors from home and abroad are available for the patients’ convenience.
Local Arjun Kunwar (38) said he had been uncomfortable even for his day to day movement due to neurological issues.

But now the problem has been normalized following the treatment he acquired on the consultation of a foreign doctor. The center made it possible for him. He underwent a surgery of his throat nerve on the recommendation of the doctor he met on the Skype at the center.

According to him, there are other many people who have been living a normal life after receiving healthcare services from the center for different health- related problems.

The center refers patients to other health facilities, in coordination with the Western Regional Hospital Pokhara, if they need to be admitted to hospital.

It was established in 2066 BS on the initiation of Char Bhanjyang Tamu Society based in the UK. Up to 25 people visit it on a daily basis these days. It welcomes people from Kushma Municipality, Mahashila Rural Municipality, Bihadi Rural Municipality as well as neighboring districts Baglung and Gulmi.

Besides all these, the center conducts a free health camps in the presence of medical experts from abroad every year targeting the locals. It has been launching a Health Education Campaign for health awareness of people. The ambulance service is in the offing.

Continue Reading

Health

Diabetes drug might ease heart failure risk

Gorkha Post

Published

on

A new research has showed that the diabetes drug Farxiga might do double-duty for patients, helping to ward off another killer, heart failure.

According to the findings were published in the New England Journal of Medicine to coincide with their presentation at the annual meeting of the American Heart Association in Chicago, Type 2 diabetics who took Farxiga saw their odds of hospitalization for heart failure drop by 27 percent compared to those who took a placebo.

Farxiga is a type of drug called a SGLT2 inhibitor. The compound is called dapagliflozin.

The study included more than 17,000 type 2 diabetes patients aged 40 and older. Nearly 7,000 had heart disease and more than 10,000 had numerous risk factors for heart disease, Wiviott’s group said.

Patients were randomly assigned to take a dummy placebo pill or 10 milligrams of Farxiga each day.

ALSO READ :  Antidepressants and other drugs cause dementia, it's confirmed

“When it comes to helping our patients control and manage blood glucose, the ‘how’ appears to be as important [as] the ‘how much,” said study author Dr Stephen Wiviott, a cardiovascular medicine specialist at Brigham and Women’s Hospital in Boston.

“When choosing a therapy, trial results like these can help us make an informed decision about what treatments are not only safe and effective for lowering blood glucose but can also reduce risk of heart and kidney complications,” Wiviott said in a hospital news release.

Taking the drug did not reduce the risk of heart attack, stroke and cardiovascular-related death, the research team noted. However, patients who took the drug did see healthy declines in their blood sugar levels, plus an added bonus: a 27 percent decrease in their risk of hospitalization for heart failure.

Their risk of kidney failure and death from kidney failure also fell, researchers noted.

Two other recent studies of this class of drugs show that they “robustly and consistently improve heart and kidney outcomes in a broad population of patients with diabetes,” Wiviott noted.

With Inputs from HealthDay

Continue Reading

TOP PICKS